biote (BTMD) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Q3 2024 revenue increased 12.8% year-over-year to $51.4 million, driven by growth in procedures and dietary supplements, with strong Amazon channel performance.
Adjusted EBITDA rose to $16.2 million (31.5% margin), up from $14.0 million (30.8% margin) in Q3 2023.
Net income for Q3 2024 was $12.7 million, with diluted EPS of $0.33, impacted by fair value changes in earnout liabilities and higher interest expense.
Strategic acquisitions in 2024, including Asteria Health, Simpatra, and BioSana, enhanced vertical integration, supply chain control, and manufacturing capabilities.
Launched enhanced clinical decision support software, expanding treatment options and patient reach, but causing temporary workflow disruptions impacting procedure volumes.
Financial highlights
Q3 2024 revenue: $51.4 million (+12.8% YoY); procedure revenue grew 7.1%, dietary supplement revenue up 21.7%.
Gross profit margin improved to 70.5% (up from 68.9% YoY), reflecting cost savings from vertical integration.
Operating income rose to $12.2 million from $7.6 million YoY; net income included a $7.2 million gain from earnout liability revaluation.
Cash and cash equivalents at quarter-end were $38.2 million, up from $26.4 million at the end of Q2 2024.
Year-to-date cash flow from operations: $32.9 million, up from $19.9 million for the same period in 2023.
Outlook and guidance
2024 revenue guidance revised to $197–$201 million and adjusted EBITDA to $58–$61 million, down from previous guidance due to software transition and hurricane-related clinic closures.
Expect continued growth from top-tier accounts, network expansion, and dietary supplement sales in Q4 2024.
Anticipate procedure revenue growth to re-accelerate in 2025 as workflow disruptions subside.
Company believes current cash, operations, and revolving loan capacity are sufficient for at least the next 12 months.
Ongoing focus on cost savings from vertical integration and margin improvement.
Latest events from biote
- 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 202511 Mar 2026 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 20242 Feb 2026 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 202426 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with robust governance in place.BTMD
Proxy Filing2 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with board-backed nominees.BTMD
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.BTMD
Proxy Filing2 Dec 2025 - Q1 net income hit $15.8M on 4.7% revenue growth; 2025 outlook and restructuring reaffirmed.BTMD
Q1 202526 Nov 2025 - Q2 2025: Dietary supplement growth, higher margins, and restructuring drove improved profitability.BTMD
Q2 202523 Nov 2025